Chemotherapy use in ovarian cancer patients diagnosed 2012–2017 in Australia, Canada, Norway and the UK: An International Cancer Benchmarking Partnership (ICBP) population-based study
Year: 2025
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: To describe use of chemotherapy in patients with ovarian cancer in national or sub-national populations of Australia, Canada, Norway and the UK. METHODS: Linked population-based data sources were used to describe use and time to chemotherapy initiation in ovarian cancer patients diagnosed in study periods during 2012-2017. Random-effects meta-analysis characterised the size of interjurisdictional variation. RESULTS: Among 39,879 patients, chemotherapy use ranged from 49 % (Wales) to 75 % (Manitoba). Across jurisdictions, chemotherapy use was higher in advanced disease (79 %, 95 %CI: 74 %-83 %), and lower for stages 1-2 or localised/regional disease (54 %, 95 %CI: 48 %-60 %). Within jurisdictions, chemotherapy use was similar in patients aged 15-64 and 65-74 and then decreased sharply with increasing age. There was large interjurisdictional variation in chemotherapy use in patients aged 85-99 years with advanced disease, being, for example, 23 % (95 %CI: 20 %-25 %) in England and 61 % (95 %CI: 51 %-70 %) in Ontario. However, jurisdictions with the highest chemotherapy use in recorded advanced stage, including Ontario, tended to have higher percentage of missing stage information. Overall, time from diagnosis to chemotherapy initiation was shorter in New South Wales and Victoria and longer in Scotland and Wales. In patients with advanced disease, interjurisdictional variation in time-to-treatment was limited. CONCLUSIONS: Even within the same age groups and stage strata, use of chemotherapy varied substantially between jurisdictions during the mid-2010s. Future work should examine use of surgery in combination with chemotherapy. The reasons for the international variation in chemotherapy use and its contribution to international variation in survival should be established.
Source: Cancer Epidemiology
Authors: Matthew E. Barclay, Sean McPhail, Shane A. Johnson, Ruth Swann, John Butler, Christian J. Finley, Andriana Barisic, Damien Bennett, Oliver Bucher, Nicola Creighton, Cheryl A. Denny, Ron A. Dewar, David W. Donnelly, Laura Downie, Norah Finn, Steven Habbous, Dyfed W. Huws, Leon May, Bjørn Møller, David S. Morrison, Grace Musto, Yngvar Nilssen, Nathalie Saint-Jacques, Lorraine Shack, Luc te Marvelde, Xiaoyi Tian, Robert J.S. Thomas, Catherine S. Thomson, Richard Walton, Tommy Hon Ting Wong, Ryan R. Woods, Hui You, Georgios Lyratzopoulos
Institutions: University College London, NHS England, Cancer Research UK, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Canadian Partnership Against Cancer, McMaster University, Cancer Care Ontario, Ontario Health, Queen's University Belfast, CancerCare Manitoba, Cancer Institute of New South Wales, Public Health Scotland, Cancer Council Victoria, Swansea University, Public Health Wales, Norwegian Institute of Public Health, Cancer Registry of Norway, Alberta Health Services, Cancer Care Alberta, The University of Melbourne, BC Cancer Agency
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,740
Funders: National Cancer Registry Ireland, Kræftens Bekæmpelse, Kreftforeningen, Public Health Wales, Cancer Research UK, Cancer Institute NSW, Cancer Society of New Zealand, Public Health Agency, Partenariat Canadien Contre Le Cancer, Cancer Council Victoria, Norwegian Institute of Public Health, Department of Health, Government of Western Australia
Awards: G4957395377, G6226316871
OpenAlex ID: W4414130786